Selected article for: "activation activation and acute ards respiratory distress syndrome"

Author: Biswas, Indranil; Khan, Gausal A
Title: Coagulation Disorders in COVID-19: Role of Toll-like Receptors
  • Cord-id: unh85vd5
  • Document date: 2020_10_29
  • ID: unh85vd5
    Snippet: Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the world. The range of the disease is broad but among hospitalized patients with COVID-19 are coagulation disorders, pneumonia, respiratory failure, and acute respiratory distress syndrome (ARDS). The excess production of early response proinflammatory cytokines results in what has been described as a cytokine storm, leading to an increased risk of thrombosis, inflammations, vascular hyperpermeability, multi-organ failure, and ev
    Document: Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the world. The range of the disease is broad but among hospitalized patients with COVID-19 are coagulation disorders, pneumonia, respiratory failure, and acute respiratory distress syndrome (ARDS). The excess production of early response proinflammatory cytokines results in what has been described as a cytokine storm, leading to an increased risk of thrombosis, inflammations, vascular hyperpermeability, multi-organ failure, and eventually death over time. As the pandemic is spreading and the whole picture is not yet clear, we highlight the importance of coagulation disorders in COVID-19 infected subjects and summarize it. COVID-19 infection could induce coagulation disorders leading to clot formation as well as pulmonary embolism with detrimental effects in patient recovery and survival. Coagulation and inflammation are closely related. In this review, we try to establish an association between virus infections associated with innate immune activation, inflammation and coagulation activation.

    Search related documents:
    Co phrase search for related documents
    • activate receptor and lps lipopolysaccharide: 1, 2, 3
    • acute increase and lps lipopolysaccharide: 1, 2
    • acute increase and lung parenchyma: 1
    • acute respiratory syndrome and lps lipopolysaccharide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung enter: 1, 2, 3, 4
    • acute respiratory syndrome and lung immune surveillance: 1
    • acute respiratory syndrome and lung microvascular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory syndrome and lung microvascular endothelial cell: 1, 2, 3
    • acute respiratory syndrome and lung parenchyma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung vasculature: 1, 2, 3, 4, 5, 6, 7, 8
    • lps lipopolysaccharide and lung microvascular: 1, 2, 3
    • lps lipopolysaccharide and lung microvascular endothelial cell: 1
    • lps lipopolysaccharide and lung parenchyma: 1